Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel [0.03%]
长期使用和依赖苯二氮卓受体激动剂减药原则：多学科专家小组的德尔菲推荐意见修正版
Jaden Brandt,Nicole Lamberson,Jolene Bressi et al.
Jaden Brandt et al.
Background: Benzodiazepine receptor agonists (BZRA) are frequently tapered because of risk of dependence and hazards of use in ageing. Standard tapering protocols may fail or result in harm from improper utilization of ph...
Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review [0.03%]
利培酮增效治疗精神分裂症阴性症状的前瞻性分析和文献综述
Ewa Okon-Rocha,David Taylor
Ewa Okon-Rocha
Cariprazine is effective in a number of conditions and has shown efficacy in the treatment of negative symptoms. Data on its use as an adjunct to other antipsychotics is growing. To evaluate the effectiveness of add-on cariprazine in patien...
Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect [0.03%]
艾司西酞普兰所致高泌乳素血症辅以阿立哌唑治疗：初步回顾性研究未见逆转效果
Xiaoqian Lan,Hongyan Zhuang,Pengfei Li
Xiaoqian Lan
Background: The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established. Objectives: To i...
Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression [0.03%]
难治性抑郁症患者接受氯胺酮或艾司氯胺酮治疗后自杀意念变化及自杀相关急诊就诊情况
Liliana Patarroyo-Rodriguez,Vanessa K Pazdernik,Jennifer L Vande Voort et al.
Liliana Patarroyo-Rodriguez et al.
Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the trea...
Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study" [0.03%]
氯胺酮鼻喷雾剂治疗难治性抑郁症5年观察研究的长期给药模式和临床结局的更正公告
[This corrects the article DOI: 10.1177/20451253261437597.]. © The Author(s), 2026.
Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians [0.03%]
瑞士医生的迷幻辅助治疗临床方法调查
Kristian Beichmann,Polina Catzeflis,Helena D Aicher et al.
Kristian Beichmann et al.
Background: The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylene...
Patient views on paliperidone palmitate 3-monthly: a cross-sectional questionnaire in UK community mental health teams [0.03%]
英国社区精神健康团队中长期注射帕利哌酮酯（每三个月一次）患者的用药感受：横断面调查研究
Ivana Clark,Siobhan Gee,David Taylor
Ivana Clark
Background: Naturalistic studies examining paliperidone palmitate 3-monthly (PP3M) long-acting injection have proven PP3M to be a safe and effective maintenance treatment for patients with schizophrenia. ...
Modafinil-associated psychosis: a systematic review of case characteristics and management strategies [0.03%]
阿莫菲尼诱发的精神病：病例特征及管理策略的系统性综述
Yutaro Sato,Atsushi Sakuma,Hiroaki Tomita
Yutaro Sato
Background: Modafinil is a wakefulness-promoting agent widely used for narcolepsy and other sleep disorders. Although considered relatively safe, psychotic episodes associated with its use have been reported. However, no ...
Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study [0.03%]
长期剂量变化及五年真实世界研究中难治性抑郁患者的临床结局分析-艾司氯胺酮鼻喷雾剂治疗难治性抑郁症：一项为期五年的观察性研究中的长期给药模式和临床结果分析
Alessandro Cuomo,Roger McIntyre,Despoina Koukouna et al.
Alessandro Cuomo et al.
Background: Treatment-resistant depression (TRD) remains a major clinical challenge, and long-term real-world data on intranasal esketamine are limited. O...
Adult psychiatrists' views on clozapine prescribing for schizophrenia in Germany-an online survey [0.03%]
德国成人精神病医师关于使用氯氮平治疗精神分裂症的见解——一项在线调查
Mishal Qubad,Ida Marie Ehret,Christian J Bachmann et al.
Mishal Qubad et al.
Background: Clozapine remains the only effective antipsychotic drug for treatment-resistant schizophrenia (TRS), yet it continues to be markedly underused in most industrialized countries including Germany. Previous studi...